Obese non-Hodgkin lymphoma patients tolerate full uncapped doses of chemotherapy with no increase in toxicity, and a similar survival to that seen in nonobese patients

References

• World Health Organization. Global status report on noncommunicable diseases 2014. Geneva: World Health Organization; 2014.
   Google Scholar
• Hijazi H, Magne N, Levy A, et al. Features of cancer management in obese patients. Crit Rev Oncol Hematol. 2013;85:193–205.
   PubMed Web of Science ®Google Scholar
• Hunter RJ, Navo MA, Thaker PH, et al. Dosing chemotherapy in obese patients: actual versus assigned body surface area (BSA). Cancer Treat Rev. 2009;35:69–78.
   PubMed Web of Science ®Google Scholar
• Powis G, Reece P, Ahmann DL, et al. Effect of body weight on the pharmacokinetics of cyclophosphamide in breast cancer patients. Cancer Chemother Pharmacol. 1987;20:219–222.
   PubMed Web of Science ®Google Scholar
• Rodvold KA, Rushing DA, Tewksbury DA. Doxorubicin clearance in the obese. J Clin Oncol. 1988;6:1321–1327.
   PubMed Web of Science ®Google Scholar
• Sparreboom A, Wolff AC, Mathijssen RH, et al. Evaluation of alternate size descriptors for dose calculation of anticancer drugs in the obese. J Clin Oncol. 2007;25:4707–4713.
   PubMed Web of Science ®Google Scholar
• Hanley MJ, Abernethy DR, Greenblatt DJ. Effect of obesity on the pharmacokinetics of drugs in humans. Clin Pharmacokinet. 2010;49:71–87.
   PubMed Web of Science ®Google Scholar
• Jain R, Chung SM, Jain L, et al. Implications of obesity for drug therapy: limitations and challenges. Clin Pharmacol Ther. 2011;90:77–89.
   PubMed Web of Science ®Google Scholar
• Field KM, Kosmider S, Jefford M, et al. Chemotherapy dosing strategies in the obese, elderly, and thin patient: results of a nationwide survey. J Oncol Pract. 2008;4:108–113.
   PubMedGoogle Scholar
• Green B, Duffull SB. What is the best size descriptor to use for pharmacokinetic studies in the obese? Br J Clin Pharmacol. 2004;58:119–133.
   PubMed Web of Science ®Google Scholar
• Madarnas Y, Sawka CA, Franssen E, et al. Are medical oncologists biased in their treatment of the large woman with breast cancer? Breast Cancer Res Treat. 2001;66:123–133.
   PubMed Web of Science ®Google Scholar
• Calle EE, Rodriguez C, Walker-Thurmond K, et al. Overweight, obesity, and mortality from cancer in a prospectively studied cohort of U.S. adults. N Engl J Med. 2003;348:1625–1638.
   PubMed Web of Science ®Google Scholar
• Griggs JJ, Mangu PB, Anderson H, et al. Appropriate chemotherapy dosing for obese adult patients with cancer: American society of clinical oncology clinical practice guideline. J Clin Oncol. 2012;30:1553–1561.
   PubMed Web of Science ®Google Scholar
• US Department of Health and Human Services; National Institutes of Health; National Cancer Institute. Common Terminology Criteria for Adverse Events (CTCAE). Version 4.03: June 14, 2010; NIH Publication No. 09-5410. Available from: http://evs.nci.nih.gov/ftp1/CTCAE/CTCAE_4.03_2010-06-14_QuickReference_8.5x11.pdf.
   Google Scholar
• Seidman A, Hudis C, Pierri MK, et al. Cardiac dysfunction in the trastuzumab clinical trials experience. J Clin Oncol. 2002;20:1215–1221.
   PubMed Web of Science ®Google Scholar
• Nurgalieva Z, Liu CC, Du XL. Chemotherapy use and risk of bone marrow suppression in a large population-based cohort of older women with breast and ovarian cancer. Med Oncol. 2011;28:716–725.
   PubMed Web of Science ®Google Scholar
• Cheson BD. The International harmonization project for response criteria in lymphoma clinical trials. Hematol Oncol Clin North Am. 2007;21:841–854.
   PubMed Web of Science ®Google Scholar
• Carson KR, Bartlett NL, McDonald JR, et al. Increased body mass index is associated with improved survival in United States veterans with diffuse large B-cell lymphoma. J Clin Oncol. 2012;30:3217–3222.
   PubMed Web of Science ®Google Scholar
• Ganti A, Liu W, Luo S, et al. Impact of body mass index on incidence of febrile neutropenia and treatment-related mortality in United States veterans with diffuse large B-cell lymphoma receiving rituximab, cyclophosphamide, doxorubicin, vincristine, prednisone. Br J Haematol. 2014;167:699–702.
   PubMed Web of Science ®Google Scholar
• Hong F, Habermann TM, Gordon LI, et al. The role of body mass index in survival outcome for lymphoma patients: US intergroup experience. Ann Oncol. 2014;25:669–674.
   PubMed Web of Science ®Google Scholar
• Lichtman MA. Obesity and the risk for a hematological malignancy: leukemia, lymphoma, or myeloma. Oncologist. 2010;15:1083–1101.
   PubMed Web of Science ®Google Scholar
• Park HY, Kwon HM, Lim HJ, et al. Potential role of leptin in angiogenesis: leptin induces endothelial cell proliferation and expression of matrix metalloproteinases in vivo and in vitro. Exp Mol Med. 2001;33:95–102.
   PubMed Web of Science ®Google Scholar
• Sanchez-Margalet V, Martin-Romero C. Human leptin signaling in human peripheral blood mononuclear cells: activation of the JAK-STAT pathway. Cell Immunol. 2001;211:30–36.
   PubMed Web of Science ®Google Scholar
• Skibola CF, Holly EA, Forrest MS, et al. Body mass index, leptin and leptin receptor polymorphisms, and non-hodgkin lymphoma. Cancer Epidemiol Biomarkers Prev. 2004;13:779–786.
   PubMed Web of Science ®Google Scholar
• Willett EV, Roman E. Obesity and the risk of Hodgkin lymphoma (United Kingdom). Cancer Causes Control. 2006;17:1103–1106.
   PubMed Web of Science ®Google Scholar
• Haim N, Epelbaum R, Ben-Shahar M, et al. Full dose vincristine (without 2-mg dose limit) in the treatment of lymphomas. Cancer. 1994;73:2515–2519.
   PubMed Web of Science ®Google Scholar
• Pfreundschuh M, Schubert J, Ziepert M, et al. Six versus eight cycles of bi-weekly CHOP-14 with or without rituximab in elderly patients with aggressive CD20+ B-cell lymphomas: a randomised controlled trial (RICOVER-60). Lancet Oncol. 2008;9:105–116.
   PubMed Web of Science ®Google Scholar
• Case DC, Jr., Desch CE, Kalman LA, et al. Community-based trial of R-CHOP and maintenance rituximab for intermediate- or high-grade non-Hodgkin lymphoma with first-cycle filgrastim for older patients. Clin Lymphoma Myeloma. 2007;7:354–360.
   PubMedGoogle Scholar
• Pettengell R, Johnsen HE, Lugtenburg PJ, et al. Impact of febrile neutropenia on R-CHOP chemotherapy delivery and hospitalizations among patients with diffuse large B-cell lymphoma. Support Care Cancer. 2012;20:647–652.
   PubMed Web of Science ®Google Scholar
• Repetto L. Greater risks of chemotherapy toxicity in elderly patients with cancer. J Support Oncol. 2003;1:18–24.
   PubMedGoogle Scholar
• Dobbs NA, Twelves CJ, Gillies H, et al. Gender affects doxorubicin pharmacokinetics in patients with normal liver biochemistry. Cancer Chemother Pharmacol. 1995;36:473–476.
   PubMed Web of Science ®Google Scholar
• Lee YT, Chan KK, Harris PA, et al. Distribution of adriamycin in cancer patients: tissue uptakes, plasma concentration after IV and hepatic IA administration. Cancer. 1980;45:2231–2239.
   PubMed Web of Science ®Google Scholar
• Pfreundschuh M, Muller C, Zeynalova S, et al. Suboptimal dosing of rituximab in male and female patients with DLBCL. Blood. 2014;123:640–646.
   PubMed Web of Science ®Google Scholar
• Extermann M, Boler I, Reich RR, et al. Predicting the risk of chemotherapy toxicity in older patients: the chemotherapy risk assessment scale for high-age patients (CRASH) score. Cancer. 2012;118:3377–3386.
   PubMed Web of Science ®Google Scholar
• Kuderer NM, Dale DC, Crawford J, et al. Impact of primary prophylaxis with granulocyte colony-stimulating factor on febrile neutropenia and mortality in adult cancer patients receiving chemotherapy: a systematic review. J Clin Oncol. 2007;25:3158–3167.
   PubMed Web of Science ®Google Scholar
• Lee S, Knox A, Zeng IS, et al. Primary prophylaxis with granulocyte colony-stimulating factor (GCSF) reduces the incidence of febrile neutropenia in patients with non-Hodgkin lymphoma (NHL) receiving CHOP chemotherapy treatment without adversely affecting their quality of life: cost-benefit and quality of life analysis. Support Care Cancer. 2013;21:841–846.
   PubMed Web of Science ®Google Scholar
• Weiss L, Melchardt T, Habringer S, et al. Increased body mass index is associated with improved overall survival in diffuse large B-cell lymphoma. Ann Oncol. 2014;25:171–176.
   PubMed Web of Science ®Google Scholar
• Vassilakopoulos T, Papageorgiou S, Angelopoulou M, et al. Prognostic significance of body mass index in patients with diffuse large B cell lymphoma treated with rituximab-CHOP or similar combinations. Hematol Oncol. 2015;33. Abstract 365
   Google Scholar